Unfractionated Heparin Monitoring for Critically Ill and General Patient Management Presented in New Educational Webinar in Honor of Medical Laboratory Professionals Week

Share Article

LabRoots will host a new webinar starting April 23 in which attendees will learn of the limitations and benefits of different unfractionated heparin (UFH) monitoring strategies.

Jerrold H Levy, MD, FAHA, FCCM Professor of Anesthesiology, Professor of Surgery (Cardiothoracic), CoDirector, Cardiothoracic ICU, Duke University Hospital

Critically ill inpatients receiving parenteral anticoagulation often receive UFH, especially for mechanical cardiopulmonary support applications. UFH is monitored by multiple tests including the activated partial thromboplastin time (aPTT), calibrated chromogenic antifactor Xa (anti-Xa) assay, or activated clotting time (ACT). Although aPTT and ACT are frequently used for UFH monitoring, these global assays have multiple preanalytical and analytical issues, along with interferences often found in critically ill patients. Anti-Xa-based heparin monitoring represents an important alternative, and can routinely be used for monitoring all institutions, regardless of size.

Webinar attendees will learn from a medical expert, Dr Jerrold H Levy who will summarize different methods for heparin monitoring in the ICU and hospital. Participants will gain a better understanding of the role of anti-Xa monitoring and clinical applications in critically ill patients. The webinar is part of a series provided within the Stago EdVantage Virtual University event in honor of the American Society for Clinical Laboratory Science’s (ASCLS) Medical Laboratory Professionals Week (MLPW).

Dr. Jerrold Levy is Professor of Anesthesiology and Surgery (Cardiothoracic) and Co-director of the Cardiothoracic Surgical Intensive Care Unit at Duke University Medical Center. He obtained his medical degree from the University of Miami, and undertook his residency and fellowships at the Massachusetts General Hospital and Harvard Medical School, Boston. His clinical and research interests include therapeutic strategies to prevent and treat bleeding; anticoagulation and its reversal, clinical applications of recombinant and purified protein concentrates, therapeutic approaches to shock/ventricular dysfunction, and anaphylaxis.

LabRoots will host the webinar starting on April 23, 2018 at 8:00 a.m. PDT. Attendees can view the webinar live at that time or join any time afterwards, earning PACE credit. Click here to learn more about the event and register for free by.

About Diagnostica Stago
Diagnostica Stago, Inc. is the exclusive provider of the Diagnostica Stago Hemostasis product lines in the United States and offers a complete system of coagulation instruments and optimized reagent kits for research as well as for routine analysis. Diagnostica Stago, Inc. is the US subsidiary of Diagnostica Stago, S.A.S. France, a leader in the development and manufacture of Hemostasis products. For more information about any Stago product or service, please call 800-222-COAG or visit our website at http://www.stago-us.com.

About LabRoots
LabRoots is the leading scientific social networking website, which provides daily scientific trending news and science-themed apparel, as well as produces educational virtual events and webinars, on the latest discoveries and advancements in science. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning, and is a primary source for current scientific news, webinars, virtual conferences, and more. LabRoots has grown into the world’s largest series of virtual events within the Life Sciences and Clinical Diagnostics community.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Karen Sorenson
LabRoots, Inc.
+1 (619) 861-0590
Email >
Visit website